NCT03633331: Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

NCT03633331
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 70 Years and older (Older Adult)
Location of Metastases: 
Additional Notes: Patients must have ER++ tumor(s)
Exclusions: Patients with untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03633331

Comments are closed.

Up ↑